NCT05417750View on ClinicalTrials.gov

A Phase I Study on Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL) for the Treatment of Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 30, 2022

Primary Completion Date

November 7, 2025

Study Completion Date

April 30, 2026

Conditions

Tumor Infiltrating LymphocytesSafetyAdvanced Solid TumorImmunotherapyEfficacyAdverse Drug Event

Interventions

DRUG

TIL therapy

A tumor sample is resected from each participant and cultured ex vivo to expand the population of autologous tumor infiltrating lymphocytes injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL followed sintilimab.

Trial Locations (1)

100039

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Shanghai Juncell Therapeutics

INDUSTRY